


IL1RAP – a future target to reduce vascular inflammation and adhesion?







¹ Cardiovascular Research Centre, Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, SWEDEN; ² Cantargia AB, SE-223 63 Lund, SWEDEN

Aim	Conclusion
To evaluate the role of inhibition of the coreceptor IL1RAP with a novel antibody, developed by the Swedish Biotech company Cantargia AB, in vascular cells.	
Results	


Blocking effect of IL1RAP antibody 3F8 on IL-1β and IL-1α induced release of inflammatory proteins in endothelial cells




IL1RAP expression correlates to markers of inflammation in human atherosclerotic plaques




The IL1RAP blocking antibody 3F8 inhibit gene expression of inflammatory cytokines in endothelial cells




IL1RAP expression correlates to ICAM expression in human atherosclerotic plaques



The IL-1 α and IL-1 β induced expression of adhesion markers affected by the IL1RAP blocking antibody 3F8 in endothelial cells




The IL-1 α and IL-1 β induced neutrophil adhesion to endothelial cells affected by the IL1RAP blocking antibody 3F8




Introduction



Cardiovascular diseases (CVDs) are the leading cause of death and inflammation is central in atherosclerosis. The atherosclerotic process starts with endothelial activation and expression of adhesion molecules followed by migration of leukocytes and smooth muscle cells, progression and ultimately stenosis or thrombosis.





The Knowledge Foundation HÖG2017 #20170191 (PI KF) HÖG2019 #20190088 (PI KF)




The IL-1 family of cytokines is central and expression of IL-1 α and IL-1 β is expressed in atherosclerotic lesions [1]. Genetic or pharmacological inhibition of IL-1 α or IL-1 β ameliorated atherosclerosis in mice [2-4]. Previously, the CANTOS study showed reduced CRP levels and reduced additional events after administration of canakinumab in patients with previous infarction [5].

References

[1] Moyer CF, et al. Am J Pathol. 1991;138:951-60. [2] Kirii H, et al. Arterioscler Thromb Vasc Biol. 2003;23:656-60. [3] Bhaskar V, et al. Atherosclerosis. 2011;216:313-20. [4] Kamari Y, et al. Atherosclerosis. 2007;195:31-8. [5] Ridker PM, et al. N Engl J Med. 2017;377:1119-1131.

Contact information



Email:

Karin H Fransén

karin.h.franzen@oru.se



Cardiovascular Research Centre Faculty of Medicine and Health Örebro University SE-701 82 Örebro SWEDEN